Envveno Medical CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
enVVeno Medical received a not-approvable letter from the FDA for its VenoValve PMA, leading to an appeal, while also facing a Nasdaq minimum bid price deficiency.
NASDAQ
10-Q: enVVeno Medical Reports Widening Losses Amid Promising VenoValve Clinical Data and Rising Cash Burn
enVVeno Medical Corporation reported increased net losses for the second quarter of 2025, driven by higher operating expenses, while advancing its VenoValve and enVVe medical device programs with positive clinical and preclinical results.
NASDAQ
enVVeno Medical Corporation reports a net loss of $4.5 million for Q1 2025, with the VenoValve PMA application under priority review by the FDA.
NASDAQ
enVVeno Medical Corporation reported a net loss of $5.6 million for Q3 2024, while also providing updates on the progress of its VenoValve and enVVe medical device programs.
NASDAQ
enVVeno Medical Corporation reported a net loss of $9.9 million for the first six months of 2024, while advancing its VenoValve and enVVe programs.
NASDAQ
10-Q: enVVeno Medical Reports Positive Clinical Trial Data for VenoValve, Prepares for FDA Submission
enVVeno Medical Corporation reports positive six-month efficacy data from its SAVVE trial for the VenoValve, with 97% of patients showing clinical improvement, and anticipates filing for FDA approval in Q4 2024.